DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03842202

CompletedPhase 1

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

72

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 30-45

Primary endpoint

•AUC of paracetamol from 0

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03842202
Org study IDNN9536-4455
Secondary ID2018-002497-42European Medicines Agency (EudraCT)
Secondary IDU1111-1215-9915World Health Organization (WHO)

Timeline

Milestones

Study first posted2019-02-15actual
Study start2019-02-15actual
Primary completion2019-11-04actual
Study completion2019-11-04actual
Last update posted2020-12-24actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Male or female, aged between 18 to 65 years (both inclusive) at the time of signing informed consent
•Body mass index (BMI) between 30.0 and 45.0 kg/m^2 (both inclusive)

Exclusion criteria

•Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method
•Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
•Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
5
Safety / tolerability / PK
4
Other (unclassified)
1

Patient-reported / QoL

5 endpoints
Secondary/protocol endpoint

Mean postprandial rating - Hunger (AUC30-300min/270 min) using visual analogue scales (VAS) from 30 up to 300 minutes during standardised breakfast meal

Time frame:Day 142

descriptive, improvement

Secondary/protocol endpoint

Mean postprandial rating - Fullness (AUC30-300min/270 min) using VAS from 30 up to 300 minutes during standardised breakfast meal

Time frame:Day 142

descriptive

Secondary/protocol endpoint

Mean postprandial rating - Satiety (AUC30-300min/270 min) using VAS from 30 up to 300 minutes during standardised breakfast meal

Time frame:Day 142

descriptive

Secondary/protocol endpoint

Mean postprandial rating - Prospective food consumption (AUC30-300min/270 min) using VAS from 30 up to 300 minutes during standardised breakfast meal

Time frame:Day 142

descriptive

Secondary/protocol endpoint

Mean postprandial rating - Overall appetite score (OAS) (AUC30-300min/270 min) using VAS from 30 up to 300 minutes during standardised breakfast meal

Time frame:Day 142

descriptive, improvement

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

AUC0-5h,para: the area under the paracetamol concentration-time curve from 0 to 5 hours at steady state

Time frame:0 to 5 hours after standardised meal (day 142)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

AUC0-1h,para: the area under the paracetamol concentration-time curve from 0 to 1 hour at steady state

Time frame:0 to 1 hour after standardised meal (day 142)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Cmax,para: the maximum observed paracetamol concentration from 0 to 5 hours

Time frame:0 to 5 hours after standardised meal (day 142)

Cmax

concentration, descriptive

Secondary/protocol endpoint

Tmax,para: the time of maximum observed paracetamol concentration from 0 to 5 hours

Time frame:0 to 5 hours after standardised meal (day 142)

Tmax

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Energy intake during ad libitum lunch

Time frame:Day 142

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.